352 related articles for article (PubMed ID: 22565095)
1. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.
Bonora E; Targher G
Nat Rev Gastroenterol Hepatol; 2012 May; 9(7):372-81. PubMed ID: 22565095
[TBL] [Abstract][Full Text] [Related]
2. Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence?
Targher G; Chonchol M; Pichiri I; Zoppini G
J Endocrinol Invest; 2011; 34(7):544-51. PubMed ID: 21427524
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease.
Yasui K; Sumida Y; Mori Y; Mitsuyoshi H; Minami M; Itoh Y; Kanemasa K; Matsubara H; Okanoue T; Yoshikawa T
Metabolism; 2011 May; 60(5):735-9. PubMed ID: 20817213
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease.
Chinnadurai R; Ritchie J; Green D; Kalra PA
Nephrol Dial Transplant; 2019 Mar; 34(3):449-457. PubMed ID: 29390103
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?
Targher G; Marra F; Marchesini G
Diabetologia; 2008 Nov; 51(11):1947-53. PubMed ID: 18762907
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease.
Targher G; Arcaro G
Atherosclerosis; 2007 Apr; 191(2):235-40. PubMed ID: 16970951
[TBL] [Abstract][Full Text] [Related]
7. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
Papademetriou M; Athyros VG; Geladari E; Doumas M; Tsioufis C; Papademetriou V
Curr Vasc Pharmacol; 2018; 16(3):254-268. PubMed ID: 28676027
[TBL] [Abstract][Full Text] [Related]
8. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?
Targher G; Chonchol M; Zoppini G; Abaterusso C; Bonora E
J Hepatol; 2011 May; 54(5):1020-9. PubMed ID: 21145850
[TBL] [Abstract][Full Text] [Related]
9. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?
Ahmed MH; Barakat S; Almobarak AO
J Obes; 2012; 2012():483135. PubMed ID: 23320150
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
Adams LA; Anstee QM; Tilg H; Targher G
Gut; 2017 Jun; 66(6):1138-1153. PubMed ID: 28314735
[TBL] [Abstract][Full Text] [Related]
12. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.
Muzurović E; Mikhailidis DP; Mantzoros C
Metabolism; 2021 Jun; 119():154770. PubMed ID: 33864798
[TBL] [Abstract][Full Text] [Related]
15. Increased Risk for Cardiovascular Events in Patients with Diabetic Kidney Disease and Non-Alcoholic Fatty Liver Disease.
Chinnadurai R; Chrysochou C; Kalra PA
Nephron; 2019; 141(1):24-30. PubMed ID: 30384370
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease.
Luo J; Xu L; Li J; Zhao S
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):193-9. PubMed ID: 25563143
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic fatty liver disease - A multisystem disease?
Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L
World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments.
Scorletti E; Calder PC; Byrne CD
Endocrine; 2011 Dec; 40(3):332-43. PubMed ID: 21894514
[TBL] [Abstract][Full Text] [Related]
19. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?
Oni ET; Agatston AS; Blaha MJ; Fialkow J; Cury R; Sposito A; Erbel R; Blankstein R; Feldman T; Al-Mallah MH; Santos RD; Budoff MJ; Nasir K
Atherosclerosis; 2013 Oct; 230(2):258-67. PubMed ID: 24075754
[TBL] [Abstract][Full Text] [Related]
20. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population.
Stepanova M; Younossi ZM
Clin Gastroenterol Hepatol; 2012 Jun; 10(6):646-50. PubMed ID: 22245962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
